The Bull Case For Celcuity (CELC) Could Change Following Strong VIKTORIA-1 Gedatolisib Phase 3 Data

Simply Wall St.03-15

Earlier this week, Celcuity announced that the Journal of Clinical Oncology published Phase 3 VIKTORIA-1 results showing the gedatolisib triplet and doublet regimens substantially reduced the risk of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619178856?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-15 02:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619178856","market":"us","top_or_hot":-1,"title":"The Bull Case For Celcuity (CELC) Could Change Following Strong VIKTORIA-1 Gedatolisib Phase 3 Data","media":"Simply Wall St.","content":"<div>\n<p>Earlier this week, Celcuity announced that the Journal of Clinical Oncology published Phase 3 VIKTORIA-1 results showing the gedatolisib triplet and doublet regimens substantially reduced the risk of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/the-bull-case-for-celcuity-celc-could-change-following-stron\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bull Case For Celcuity (CELC) Could Change Following Strong VIKTORIA-1 Gedatolisib Phase 3 Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bull Case For Celcuity (CELC) Could Change Following Strong VIKTORIA-1 Gedatolisib Phase 3 Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-15 02:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/the-bull-case-for-celcuity-celc-could-change-following-stron><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this week, Celcuity announced that the Journal of Clinical Oncology published Phase 3 VIKTORIA-1 results showing the gedatolisib triplet and doublet regimens substantially reduced the risk of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/the-bull-case-for-celcuity-celc-could-change-following-stron\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/the-bull-case-for-celcuity-celc-could-change-following-stron","article_id":"2619178856","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/the-bull-case-for-celcuity-celc-could-change-following-stron","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619178856","pubTimestamp":1773513256,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this week, Celcuity announced that the Journal of Clinical Oncology published Phase 3 VIKTORIA-1 results showing the gedatolisib triplet and doublet regimens substantially reduced the risk of disease progression or death versus fulvestrant alone in HR-positive, HER2-negative PIK3CA wild-type advanced breast cancer after CDK4/6 inhibitor and aromatase inhibitor therapy.\nThe data highlight gedatolisib’s differentiated, multi-target PAM pathway inhibition, which produced a 7.3-month...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CELC":"Celcuity Inc"},"translate_title":"Viktoria-1 gedatolisib 3期数据强劲后，Celcuity(CELC)的牛市可能会发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":1.5},"content_text":"Earlier this week, Celcuity announced that the Journal of Clinical Oncology published Phase 3 VIKTORIA-1 results showing the gedatolisib triplet and doublet regimens substantially reduced the risk of disease progression or death versus fulvestrant alone in HR-positive, HER2-negative PIK3CA wild-type advanced breast cancer after CDK4/6 inhibitor and aromatase inhibitor therapy. The data highlight gedatolisib’s differentiated, multi-target PAM pathway inhibition, which produced a 7.3-month improvement in median progression-free survival for the triplet regimen compared with fulvestrant, potentially addressing both PIK3CA-mutant and wild-type tumors more comprehensively than single-target inhibitors. With these VIKTORIA-1 results reinforcing gedatolisib’s clinical profile, we’ll examine how this could influence Celcuity’s investment narrative and commercialization path. Find 48 companies with promising cash flow potential yet trading below their fair value.AdvertisementCelcuity Investment Narrative RecapTo own Celcuity, you need to believe gedatolisib can convert strong late stage breast cancer data into regulatory approval and meaningful use in practice. The Journal of Clinical Oncology publication sharpens that thesis, but the key short term catalyst remains the upcoming FDA decision on the NDA, while the biggest current risk is that approval timing or requirements differ from expectations. Closely tied to this update, the FDA’s priority review of gedatolisib’s NDA, with a mid July 2026 PDUFA date, is the announcement that matters most here. The newly published VIKTORIA 1 wild type results help underpin that filing, but the market will ultimately focus on how the agency weighs efficacy, safety and the multi target PAM profile when deciding on first approval and any labeling details. Yet investors should also be aware that if regulators delay or require additional data on gedatolisib, Celcuity’s path to commercialization and profitability could... Read the full narrative on Celcuity (it's free!)Celcuity's narrative projects $607.1 million in revenue and $152.4 million in earnings by 2029. This implies an earnings increase of about $315 million from -$162.7 million today.Uncover how Celcuity's forecasts yield a $116.70 fair value, in line with its current price.Exploring Other PerspectivesCELC 1-Year Stock Price Chart Three Simply Wall St Community fair value estimates for Celcuity span about US$117 to over US$553 per share, showing how far apart individual views can be. When you set those against the binary nature of upcoming FDA decisions, it underlines why many investors seek out multiple perspectives before forming a view on Celcuity’s prospects.Explore 3 other fair value estimates on Celcuity - why the stock might be worth over 4x more than the current price!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Celcuity research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free Celcuity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celcuity's overall financial health at a glance.Ready For A Different Approach?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619178856","isCrawlerRequest":true}